please fine me at BlueSky - not here on twitter/x any more
New York, NY
Joined March 2013
- Tweets1.8K
- Following591
- Followers4.7K
- Likes3.7K
Pinned Tweet
This will be my last post here for presumably some time. I can’t in good conscience remain on this platform. Time to figure out BlueSky. There is so much wrong with our society right now, almost all beyond my control. But for me remaining on Twitter has become unconscionable.
Matthew Matasar, MD retweeted
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma. #lymsm | @DrMatasar
cancernetwork.com/view/prior…
Matthew Matasar, MD retweeted
Advances in MCL and FL from #ASH24. With
@SehnLaurie of @BCCancer, @timfenske of @MedicalCollege, @poh_christina of @fredhutch & @UW, Dr Sunita Nasta of @PennCancer, @LymphClinician of @cityofhope, @DrMatasar of @RutgersCancer, and more. #lymsm cancertherapyadvisor.com/ind…
Odronextamab post-CAR: glad to have shared our updated data from #ELM1 with @OncLearnNetwork at #ASH24 hmpgloballearningnetwork.com…
Matthew Matasar, MD retweeted
Don’t miss @DrMatasar’s oral presentation today at #ASH24 highlighting innovative findings from the ELM-1 study on the efficacy and safety of odronextamab monotherapy for patients with relapsed/refractory #DLBCL. Learn more about the research here: bit.ly/4eR8T8I
#ASH24 come check out the VR and digital avatars with Encompass - moving education around bispecifics into the future!
Matthew Matasar, MD retweeted
👏👏 Kudos to adult & pediatric Chiefs @DrMatasar & Peter Cole for GREAT achievement at the @ASH_hematology #hematology symposium this year (6⃣6⃣ at the 6⃣6⃣th #ASH24).
🎉🎉An extra call-out to @drjoannarhodes1 directing the #lymphoma program to nearly 50 lymphoid presentations!
Physician-scientists from @RutgersCancer and @RWJBarnabas will present 66 abstracts at the 66th @ASH_hematology Annual Meeting (Dec 7-10, 2024).
The research spans critical topics in hematology/oncology, advancing treatments and outcomes for blood cancers and disorders like sickle cell disease, #lymphoma, #leukemia, and #myeloma.
cinj.org/rutgers-cancer-inst…
#ASH24 #BloodCancerResearch #HematologyOncology #CancerResearch
Hope to see you at #ASH24 - should be a great session alongside superstars 💫 @chanyooncheah @UjjaniC @nishjo76 and @End_myeloma 💫
📊 Stay updated on the standards of care for hematologic malignancies and enhance your skills in community-based management. 💉 Gain confidence in tailoring patient-centric treatment plans for optimal outcomes. Join our expert @DrMatasar 📍 ms.spr.ly/6011WMkdJ
#ASH24
Matthew Matasar, MD retweeted
Exploring the Management of Cytokine Release Syndrome With @JenCrombieMD @DanaFarber @harvardmed and @DrMatasar @RutgersCancer
targetedonc.com/view/explori…
Great conversation with @JenCrombieMD about #bispecifics #bsab with a focus on deploying them in community settings!
In this series, experts discuss how to operationalize bispecific antibody therapy in community practices. @JenCrombieMD @DanaFarber @harvardmed @DrMatasar @RutgersCancer @missioncancer_
targetedonc.com/view/cd3-cd2…
Matthew Matasar, MD retweeted
📊 Stay updated on the standards of care for hematologic malignancies and enhance your skills in community-based management. 💉 Gain confidence in tailoring patient-centric treatment plans for optimal outcomes. Join our expert @DrMatasar 📍 ms.spr.ly/6011WMkdJ
#ASH24
Enjoyed talking with @JenCrombieMD about the present (and future!) of #bispecifics in B-cell lymphoma!
Experts discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T-cell engagement and targeting malignant B cells effectively. @JenCrombieMD @DanaFarber @RutgersCancer
targetedonc.com/view/intro-a…
Proud to share that @RutgersCancer has successfully treated our 200th patient with #CART therapy. And we’re only getting started, with NJ’s only CAR-T GMP facility and leadership in innovative clinical trials! cinj.org/200th-car-t-cell-th…
Way to go Dr.Tiger! @WomenInLymphoma #risingstar
This quoted post is unavailable.
Looking forward to today's session on the evolving role for #BTK inhibitors in first-line treatment of #MCL with my friend and MCL expert Dr. Anita Kumar (not on twitter!) @medliveofficial bit.ly/3xpNMud
OLYMPIA-3 is a trial-in-progress for patients with newly diagnosed DLBCL evaluating O-CHOP (odronextamab + chop). Spoke with @OncLearnNetwork to give the skinny - thrilled to be trying to move #bispecifics to the first line! @Regeneron
hmpgloballearningnetwork.com…
Matthew Matasar, MD retweeted
📶 We continue to grow!
See below for a new BMT & CART faculty/physician position at @RWJBarnabas & @RutgersCancer. Be part of a dynamic & highly collaborative #BloodCancer team, led by @DrMatasar (cinj.org/patient-care/adult/…).
nejmcareercenter.org/job/775…
1/3
My secret to being a good doc is working with great nurses and APPs. So a special shout out to the Heme Malignancy nurses that *dominated* our nursing awards! Kim Laino (who’s been w me through it all!), Kira Lynn Voitle, Kathy Kafka, Joyce Herrera - so proud! @RutgersCancer
Three #nurses have been named recipients of @RutgersCancer’s ‘Oncology Nursing Excellence Awards’ during #NursesWeek this year. Thank you to all our amazing nurses! 👏
cinj.org/honoring-oncology-n…
@RWJBarnabas #OncologyNursingMonth #oncologynurses
Such shocking and terrible news. Please have his family in your thoughts, and consider supporting his family if you have the means.
💔 We are devastated and heartbroken by the death of Bryan Soltes at age 48. A true gentle giant (ex @UDelaware student athlete & @RamsNFL player, then healthcare administrator w/ @RCCANETWORK & @RWJBarnabas), he was an incredibly bright, kind, and compassionate man who fought every day for cancer patients.
Please think of his loving wife Jeannie, and his three daughters. Bryan, my friend, please rest in peace. 🙏
Support the Family of Bryan Soltes:
gofund.me/a9f7a256
